Acute coronary syndromes research
Associate Professor James Shaw is the Principal Investigator for a number of clinical trials that target the Acute Coronary Syndrome (ACS) population new treatments in Hyperlipidemia and Atrial Fibrillation.
Associate Professor James Shaw provides patients both inpatients and outpatients at Alfred Health an opportunity to gain access to new research treatments before they are widely available. Ensuring his patients an opportunity to partake in clinical trial or studies as another avenue of clinical treatment and care is a key passion of Dr Shaw’s. Having updated and emerging practices is a key focus for our cohort of patients. These projects consist of both pharmaceutical sponsored trials and internal investigator-initiated studies.
Dr James Shaw and the clinical trial team ensure patients receive regular and careful medical attention. Some of our current trials are Prevail (Obicetrapid), treatments that reduce LDL levels and increasing HDL levels in a patient cholesterol profile, thus reducing future incidents in ACS events. Oceanic AF (Asundexian) new advance NOACs in Atrial Fibrillation treatment. Core (Olezarsen) new treatments in hypertriglyceridemia where traditional therapies have not been sufficient.
Associate Professor James Shaw is one of the Deputy Directors and Head of Education and Training in Cardiology, and has held this position since 2014.
Our partners
Publications
Kaye, David M; Nanayakkara, Shane; Wang, Bing; Shihata, Waled; Marques, Francine Z; Esler, Murray; Lambert, Gavin; Mariani, Justin
(2022), JACC-BASIC TRANSL SC, 7(2), 116-127
Vatani, A, Liao, S, Burrell, A J C, Carberry, J, Azimi, M, Steinseifer, U, Arens, J, Soria, J, Pellegrino, V, Kaye, D, Gregory, S D
(2022), ASAIO J, 2, 205-213
Donaldson, L H, Hammond, N E, Agarwal, S, Taylor, S, Bompoint, S, Coombes, J, Bennett-Brook, K, Bellomo, R, Myburgh, J, Venkatesh, B
(2022), CRIT CARE RESUSC, 1, 20-28
DOI: 10.51893/2022.1.OA3
